Pharma Mar, S.A. (PHMMF)

Market Cap	1.49B
Revenue (ttm)	222.27M
Net Income (ttm)	49.34M
Shares Out	n/a
EPS (ttm)	2.83
PE Ratio	30.26
Forward PE	19.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	152
Average Volume	54
Open	93.00
Previous Close	93.00
Day's Range	93.00 - 93.00
52-Week Range	75.00 - 110.40
Beta	-0.01
RSI	31.19
Earnings Date	Oct 30, 2025

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: OTCMKTS
• Ticker Symbol: PHMMF

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.

Financial numbers in EUR